We assessed the effects of donor age on clonogenicity, proliferative potential, and spontaneous γH2AX foci in the proliferating (Ki67 +) and senescent (SA β-gal +) cultures of skin fibroblasts isolated from 34 donors of different age (23-82 years). Here, we demonstrated that neither the colony forming effectiveness of proliferating (Ki67+) fraction of the fibroblasts nor the average number of γH2AX foci of the same fraction does not depend on the age of the donor. The correlation between the number of γH2AX foci and the donor's age was reliable in quiescent (Ki67-) cells. The average number of γH2AX foci in quiescent fibroblasts of donors older than 68 years was about two times higher than in the same cells of up to 30 years old donors. The number of γH2AX foci demonstrated a statistically significant positive correlation with the fraction of proliferating cells in fibroblast cultures. On average, proliferating cells have twice as many the γH2AX foci in comparison with the quiescent cells. Within a population of proliferating (Ki67+) cells, the degree of senescence correlated with a relative declining of constitutive γH2AX foci number, whereas in the population of quiescent (Ki67-) cells, it was proportional to augmenting the number of the γH2AX foci. Our data on a statistically significant (p=0.001) correlation between the age of the donor and the number of constitutive γH2AX foci in quiescent cells, could point out the ongoing DNA-damage response due in the maintenance of the senescent state of cells.
24 April 2023 in Russian Journal of Clinical Dermatology and Venereology
In aging, two types of fundamental molecular mechanisms in the skin are involved. One of them involves the main cell population of the dermis, fibroblasts, their number and functional activity; the other is associated with a homeostasis disorder of the extracellular matrix (ECM) of the dermis and its main structural component, collagen. With age, the population of dermal fibroblasts is decreasing, primarily due to the depletion of precursor cells, leading to a decrease in the regenerative potential of the skin tissue. At the same time, there are structural, quality, and functional disorders of the dermal ECM associated with its ultrastructural, morphometric, mechanical, and conformational changes, which entail a dysfunction of dermal fibroblasts. The latter contributes to the positive feedback that stimulates further ECM degradation. All these destructive processes form a vicious circle, leading to the constant progression of skin aging. This article describes the cellular and molecular mechanisms of these processes. Their study and understanding are significant since it opens the way for a competent solution and the search for new approaches to solving the extremely urgent skin aging problem.
25 April 2025 in Russian Journal of Clinical Dermatology and Venereology
A detailed review of current products and innovative strategies of gene and cellular therapy, which are at different study phases, in the treatment of recessive dystrophic epidermolysis bullosa (RDEB) is provided. The most promising in cellular RDEB therapy is application of allogenic mesenchymal stromal/stem cells that can be injected intradermally and intravenously. Genetically modified autologous dermal fibroblasts, which are injected intradermally along the wound edges also should be noted among the injection methods. Epidermal transplants, based on patient’s autologous keratinocytes, have been developed ex vivo on the basis of gene therapy methods. Products based on double-layer transplants, including both types of skin cells producing C7, have been developed as well. These are the most advanced technologies in pre-clinical and clinical studies, and the gene product in vivo, namely a local gene therapy on the basis of herpes simplex virus type 1 aimed at C7 protein restoration by delivering COL7A1, is the first method of gene therapy, that can already be used in a clinical setting for RDEB treatment. Products based on gene editing using nucleases are also being developed. The review discusses in detail the results of pre-clinical and clinical studies of above mentioned products.
11 November 2025 in Russian Journal of Clinical Dermatology and Venereology
Recessive dystrophic epidermolysis bullosa (RDEB) is one of the main types of epidermolysis bullosa, a rare, severe, genetic disease characterized by systemic chronic inflammation, blisters, erosions and extensive chronic wounds on the skin and a tendency to squamous cell carcinoma development. The disease is caused by pathogenic variant of COL7A1 gene encoding the synthesis of type VII collagen (C7), that is the main component of the anchorage fibrils, which maintain the adhesion between the epidermis and the underlying dermis. The disease is debilitating. Treatment methods mainly include supportive measures so the development of treatment methods that directly affect the cause of the disease is very relevant. The article is devoted to the possibility of using one of the most promising treatment strategies of RDEB — gene editing in patients with RDEB by means of specific nucleases, namely TALEN (Transcription activator-like effector nucleases) and CRISPR/Cas (Clustered Regularly Interspaced Short Palindromic Repeats/Crispr-Associated protein) that allows to almost irreversibly restore the C7 synthesis. The method is at preclinical stage. The results of preclinical studies, comparative analysis of used methods, as well as approaches that may help to implement this method of RDEB gene therapy in clinical practice in the nearest future are presented.
10 September 2025 in Russian Journal of Clinical Dermatology and Venereology
Recessive dystrophic epidermolysis bullosa is one of the most severe hereditary diseases molecular pathology of which is associated with biallelic mutation variants with loss of function in COL7A1 gene coding type VII collagen (C7). In this regard, one of the main approaches of RDEB gene therapy is the development of gene replacement therapy methods that involves substitution of a mutant gene allele to exogenous full-length wild type gene by transduction of the latter in the skin cells. The development is carried out in two directions — ex vivo to obtain transgenic skin equivalents (both mono- and bilayer) and in vivo — application of the gene product directly in the patient’s body. In particular, a gene product for topical use (Beremagene geperpavec, B-VEC) has been developed and already introduced into clinical practice, action of which is aimed at restoring C7 synthesis by both types of skin cells producing this protein. The article is devoted to methods of gene replacement therapy for treatment of patients with recessive dystrophic epidermolysis bullosa. The results of pre-clinical and clinical trials as well as developed gene products, vectors of their delivery to the skin, prospects for development of this area of gene therapy and challenges ahead are described in detail.
1 July 2025 in Russian Journal of Clinical Dermatology and Venereology
Recessive dystrophic epidermolysis bullosa (RDEB) is a rare hereditary disease characterized by a high skin susceptibility, formation of bubbles, erosions, chronic lesions, chronic systemic inflammation. The use of mesenchymal stem/stromal cells (MSCs) isolated from different sources can be considered as one of the RDEB treatment methods. MSCs are an ideal candidate for treating a wide range of serious diseases due to the simplicity of their isolation and reproduction, the ability to differentiate into multiple cell lines, the ability to neovasculogenesis, as well as in consequence of the pronounced paracrine effect through the production of anti-inflammatory, immunomodulating, antiapoptotic, antifibrotic and anabolic factors, that leads to damaged tissues’ recovery. At the same time, MSCs have a low immunogenicity that allows to use allogenic MSCs (without the need for aggressive patient’s conditioning as in the case of allogenic transplantation of bone marrow cells), that is especially relevant due to the RDEB nature associated with systemic inflammation. This therapy can significantly decrease the disease activity and improve the life quality of patients with RDEB by reducing inflammatory processes in the body and relieving persistent and highly disturbing symptoms — itching and pain. The article summarizes the mechanisms by which MSCs contribute to healing skin lesions, systemic anti-inflammatory effect in the treatment of patients with RDEB. The results of pre-clinical and clinical studies have been also discussed.